Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends

Looking for stocks that wage dividends? You whitethorn person travel crossed pharmaceutical outfit Pfizer (NYSE: PFE) successful your search. After all, its forward-looking dividend output of 7.1% is 1 of the highest among bluish spot stocks close now.

So however galore shares of this drugmaker would you request successful bid to collect, say, $5,000 worthy of yearly dividend income? If you annualize its quarterly per-share outgo of $0.43, 2,907 shares would bash the trick. That's astir $69,940 worthy of this stock, assuming you're getting successful astatine today's price.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

The question is: Is this really a banal you tin number connected to proceed paying -- and increasing -- its dividend?

Preparing for the aboriginal

The increasing interest present is the impending expiration of the patents protecting respective of Pfizer's breadwinning drugs. These see the humor thinner Eliquis, cancer-fighting drugs Ibrance and Xtandi, and pneumonia vaccine Prevnar 13. All of these volition suffer patent extortion wrong the adjacent mates of years, posing a menace to astir one-third of the company's revenue.

But instrumentality a measurement backmost and look astatine what the institution has done -- and is doing -- to hole for this inevitable tumble disconnected the patent cliff. Since 2022, it has acquired Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, Seagen, and Metsera.

These deals person brought drugs with varying degrees of readiness and marketability nether Pfizer's umbrella, but they've dramatically boosted its imaginable successful the oncology and anti-obesity markets. All told, the pharmaceutical outfit intends to bring astatine slightest 8 caller blockbuster drugs to marketplace arsenic a effect of these acquisitions, though much are surely possible.

The lone catch? We won't commencement seeing meaningful impacts from these investments until aft 2028.

All this dealmaking hasn't precisely been cheap, either. It's inactive arguably been worthy it, though, peculiarly to income investors. While it whitethorn not thrust widening profits oregon nutrient chaotic nett growth, it volition supply reliable currency travel that supports continued dividend payments.

Should you bargain banal successful Pfizer close now?

Before you bargain banal in Pfizer, see this:

The Motley Fool Stock Advisor analyst squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Pfizer wasn't 1 of them. The 10 stocks that made the chopped are built for semipermanent maturation and could nutrient monster returns successful the coming years.